Magellan updates three clinical practice guidelines; adopts ASAM criteria for SUD
Revisions for ADHD, ASD, and managing the suicidal patient available online
Magellan’s clinical taskforce recently approved updates to three of the organization’s clinical practice guidelines (CPGs). These guidelines serve as the evidence-based framework for practitioners’ clinical decision-making for the treatment of patients.
In addition, Magellan adopted the American Society of Addiction Medicine (ASAM) clinical practice guidelines for substance use disorders.
Highlights of the 2020 changes:
Attention-deficit/hyperactivity disorder (ADHD)
The 2019 American Academy of Pediatrics clinical practice guideline updates the former reference in the Magellan CPG and, in addition, was adopted as a separate, externally developed CPG:
- The American Academy of Pediatrics’ (AAP) Clinical Practice Guideline for Diagnosis, Evaluation and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents (2019)
- AAP’s companion document to the guideline, Systemic Barriers to the Care of Children and Adolescents with ADHD
Per the AAP, this version updates and replaces the 2011 practice guideline and indicates incremental updates to the previous version. The introduction section to the AAP guideline outlines several of these updates, such as a key action statement about the diagnosis and treatment of coexisting or comorbid conditions.
Autism spectrum disorders (ASD)
Magellan re-adopted the American Academy of Pediatrics (AAP) guideline, which was recently updated by the AAP.
- Identification, Evaluation, and Management of Children with Autism Spectrum Disorder (2020)
As indicated in the Executive Summary of the updated clinical report: “In the years since 2007, when the American Academy of Pediatrics published the clinical reports ‘Identification and Diagnosis of Children with Autism Spectrum Disorders’ and ‘Management of Children with Autism Spectrum Disorders,’ reported prevalence rates of children with ASD have increased, understanding of potential risk factors has expanded, awareness of co-occurring medical and behavioral conditions and genetic contribution to etiology has improved, and the body of research supporting evidence-based interventions has grown substantially. The updated document discusses evaluation and treatment as a continuum in one publication with a table of contents to help the reader identify topic areas within the report...”
(Hyman SL, Levy SE, Myers SM, AAP COUNCIL ON CHILDREN WITH DISABILITIES, SECTION ON DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS. Executive Summary: Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. Pediatrics. 2020;145(1):e20193448.https://doi.org/10.1542/peds.2019-3448).
Managing the suicidal patient
Magellan adopted the following practice guideline and incorporated relevant content into its own guideline update:
- VA/DoD Clinical Practice Guideline for the Assessment and Management of Patients at Risk for Suicide (2019, version 2)
Substance Use Disorders (SUD)
Magellan most recently adopted the following additional clinical practice guidelines for SUD:
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: Focused Update (2020)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020)
Previously adopted guidelines
The Magellan taskforce removed some previously adopted or developed guidelines from their regular review and update; however, these remain available to providers as portions of the documents are pertinent to current clinical practice. The CPGs for generalized anxiety and obsessive-compulsive disorders were recently moved to this status.
Have feedback to share?
Magellan’s adopted guidelines are intended to augment, not replace, sound clinical judgment.
We welcome your feedback and will consider all suggestions and recommendations in our next review. You may submit comments to your regional Magellan provider advisory group, medical director or to CPG@MagellanHealth.com.